Drugs / anti-OX40
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01303705 | Oct 2010 → Jul 2016 | metastatic prostate carcinoma | Providence Health & Services | Completed | No outcome recorded |
| Phase 1 | NCT01644968 | Nov 2003 → May 2009 | cancer of unknown primary site | Providence Health & Services | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01416844 | Sep 2012 | metastatic melanoma | Providence Health & Services | Withdrawn | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-06-27 | Sanofi | Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody sanofi.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-OX40 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01416844 ↗ |
| Action | Activate | “a mouse monoclonal antibody (mAb) that agonizes human OX40 signaling” PMID 24177180 ↗ Oct 2013 |
| Modality | Monoclonal antibody | “Monoclonal Antibody to OX40” NCT01303705 ↗ |
| Route | Intravenous | “Anti-OX40 will be administered intravenously” NCT01303705 ↗ |